The new Accelerating Rare Disease Cures program at the US Food and Drug Administration may be as much about relieving external pressure to make a more drastic reorganization than about coordinating rare disease activities.
The ARC program, which rests in the Center for Drug Evaluation and Research, is intended to speed development of rare...







